Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A Y LeeRandy D Gascoyne

Abstract

To examine the clinical course of patients who experienced a late relapse after initial curative chemotherapy for advanced-stage diffuse large-cell lymphoma. Between April 1981 and June 1986, 127 patients with de novo advanced-stage diffuse large-cell lymphoma were treated with a 12-week chemotherapy program (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin [MACOP-B]). The overall survival rate at 10 years is 52%. One hundred six patients (83%) entered a complete remission (CR) and 43 of them relapsed. With a median follow-up duration of 146 months, 26 patients relapsed early and 17 relapsed late, ie, after a continuous CR (cCR) of greater than 24 months. All late relapses occurred in patients with B-cell lymphoma. After 24 months from diagnosis, the rate of late relapse averaged 2.2% per year and reached a projected 22% actuarial risk of late relapse after 10 years. The median time to late relapse was 69 months (range, 38 to 141). Ten patients relapsed with aggressive histologic subtypes and were treated with curative intent using anthracycline-based chemotherapy. Four remain in second CR, one is alive with disease, and five died of disease or while on treatment. The 6-year overall survival r...Continue Reading

Citations

Nov 13, 2004·Annals of Hematology·Michael A FridrikWillhelm Oberaigner
Apr 11, 2003·Leukemia & Lymphoma·Andrew H Ko, Alan R Yuen
Aug 7, 2019·British Journal of Haematology·Barbara VannataEmanuele Zucca
Sep 13, 2001·Clinical and Laboratory Haematology·K M BowlesR E Marcus
Oct 25, 2014·Annals of Surgical Oncology·Eran SadotRonald P DeMatteo
Jun 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yucai WangGrzegorz S Nowakowski
Nov 27, 2004·Acta Haematologica·Akitoshi NagasakiMasato Masauda
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-François LaroucheBertrand Coiffier
Jan 6, 2017·Case Reports in Cardiology·Baljit SinghTarik Hadid
Oct 1, 2010·British Journal of Haematology·Julie M VoseJames O Armitage
May 17, 2005·Journal of Neurology·Ulrich HerrlingerMichael Weller
Jul 16, 2019·Mathematical Biosciences·Nicolas Houy, François Le Grand
Oct 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K J SavageJ M Connors

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C TondiniG Bonadonna
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
U PopatK van Besien
The New England Journal of Medicine
Mark S KaminskiRichard L Wahl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Tamara N ShenkierJoseph M Connors
© 2021 Meta ULC. All rights reserved